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Abstract. In the development and progression of cancer,
tumor suppressor genes may be silenced by mechanisms such
as methylation. Thus the discovery of new genes silenced by
methylation may uncover new tumor suppressor genes, and
improve our understanding of cancer biology. In this study
we investigated the methylation of 19 genes in esophageal
squamous cell carcinoma. Methylation was measured in 10
of these genes in esophageal squamous cell carcinoma cell
lines: CDH13, CLDN6, C16orf62, FBN2, FNBP1, ID4, RBP1,
RBP4, TFPI2 and TMEFF2. To determine if there was a
correlation between DNA methylation and gene silencing,
each cell line was cultured with or without the demethylating
drug 5-aza-2'-deoxycytidine (aza-dC). For 6 genes (CLDN6,
FBN2, RBP1, RBP4, TFPI2 and TMEFF2) there was an
association between reduction of methylation and increase in
mRNA expression in the demethylated cell lines. The
frequency of the methylation of these 6 genes in esophageal
squamous cell carcinoma resection specimens was also
investigated. All 6 genes showed more frequent methylation
in the tumor than the matched proximal resection margin of
uninvolved esophagus. There was a significant difference in
the frequency of methylation and in the extent of the
methylation between the cancer and the margin tissues for
CLDN6, FBN2, TFPI2 and TMEFF2 (P=0.0007, P=0.0048
P=0.0002 and P<0.0001, respectively). This is the first report
of gene silencing by methylation of CLDN6, FBN2, RBP4,
TFPI2 and TMEFF2 in esophageal squamous cell carcinoma. 
Introduction
Esophageal cancer is one of the most lethal of malignancies
and worldwide is the sixth most common cause of death from
cancer (1). Despite many refinements in surgery, chemo-
therapy, radiotherapy, and combined therapy, the 5-year
survival rate remains around 10% (2). The two most common
histological types of esophageal cancer are squamous cell
carcinoma and adenocarcinoma. While there has been a
recent, rapid increase in the incidence of adenocarcinoma in
Western countries, including Australia (3-6), squamous cell
carcinoma remains the most common form of esophageal
cancer worldwide. Understanding the molecular pathology of
such cancer may advance therapeutic and diagnostic strategies
for these clinically important cancers.
The development and progression of esophageal squamous
cell carcinoma is described as a multistep process, with a
transition from normal to a hyperproliferative squamous epi-
thelium, and then through low-, intermediate- and high-grade
dysplasia/carcinoma in situ to invasive carcinoma. Through
these sequential pathological changes there is an increasing
atypia compared to normal squamous epithelium, and an
increasing risk for the development of esophageal squamous
cell carcinoma (7). Although the histological progression
of esophageal squamous cell carcinoma is relatively well
established, our knowledge of the molecular events which
parallel or underlie this progression is more limited, especially
in terms of activation of oncogenes or inactivation of tumor
suppressor genes. The changes in cellular phenotype are
thought to result from the dysregulation of gene expression
and/or protein function, attributable to genetic and/or epi-
genetic changes. A common epigenetic change which can
cause transcriptional silencing of genes, including tumor
suppressor or growth-regulatory genes, is methylation of CpG
islands associated with the promoter region of these genes
(8). Detection of methylation of CpG islands may reveal
novel tumor suppressor genes, and provide insights into the
underlying tumor biology.
In a previous study we discovered 19 new genes commonly
silenced by methylation in esophageal adenocarcinoma
(9,10). To broaden our understanding of the importance
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of these genes in cancer we have measured their methylation
in esophageal squamous cell carcinoma cell lines and in
tissues resected from patients with esophageal squamous
cell carcinoma.
Materials and methods
Cell cultures. Triplicate cultures of the esophageal squamous
cell carcinoma cell line OE21 were grown in RPMI-1640,
supplemented with 10% fetal bovine serum (FBS), at 37˚C
in air with 5% CO2. Triplicate cultures of the esophageal
squamous cell carcinoma cell lines KYSE-170, KYSE-510,
KYSE-1170 (11,12) were grown in Ham's F-12/RPMI-1640
with 2% FBS at 37˚C in air with 5% CO2, and SUm/c (12) the
same except for 5% FBS.
Demethylation of esophageal squamous cell carcinoma cell
lines by aza-dC treatment. The cell lines were seeded into
flasks and cultured for 24 h, and then for a further 72 h
in culture medium to which had been added either vehicle
or 1 μM aza-dC (Sigma-Aldrich, St. Louis, MO, USA) as
previously described (13). Preliminary experiments showed
that these conditions were sufficient for at least two cell
divisions. The cells were then cultured for a further 24 h in
fresh medium without aza-dC or vehicle before harvesting.
Patients and surgical specimens. Tumor and corresponding
uninvolved squamous epithelium from the proximal
resection margin were obtained from patients who had had
an esophagectomy for primary esophageal squamous cell
carcinoma at the 4th Hospital of Hebei Medical University,
Shijiazhuang, P.R. China. The tissues were collected into
RNAlater (Ambion, Austin, TX, USA). Informed consent
was obtained from the patients for the use of the resected
samples for research. The study complied with the appropriate
institutional guidelines.
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Table I. The summary of primers used in this study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene Forward primer (5'>3') Reverse primer (5'>3') Annealing
temperature
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Methylation
BNIP3 TYGGTTTYGTTTTGTTTTGTGAGTTTT CCRAACTACRAAATATACTTCAACTA 55
CDH13 GATTTATTTGGGAAGTTGGTTGGT CRAAATTCTCRACTACATTTTAT 55
CLDN6 AGGYGGGTTTAGYGATTTTAGTT AATTCCTAAACCRAATATCRAAACAAA 55
C16orf62 GTTAGTTGAAAATGAAGTTTGTGT CCRCCATATTTATAAAAAACAACTAA 55
DCBLD2 GGGTGGGAYGTTTTTAAAGGT ACCAATCCTCRACCAACTCTAA 55
FBN2 TYGTTYGGTTTYGTAGTYGTTAT CRAATATTAAAAAACTACAAAAATCACCAA 55
FNBP1 GTTGTTAGGGGAAAGTATTGTTT AATAATAACTTCTTAATAACCACTATCTA 55
ID4 GGGGYGTAYGGTTTTATAAATATAGTTG TAATCACTCCCTTCRAAACTCCRACTAAA 55
MLF1 GAGTAATGTTTAATGGGAAAGTAGT CATCCTAAACATTCTAACTCTATCTTA 55
NRG1 GTGYGAAGGAGGYGTTTGTTT CCRCCRCTCAACTCCTAA 57
PRDM2 GAATTTTTGAATTAYGTAGGATTTTAGT CCCAATAACCACCACCCAA 60
RBP1 TGTGYGYGTTGGGAATTTAGTTG CRAAAAATAACTAAAACCAATTAACCACAAA 55
RBP4 TTAGGGYGYGTTATGTAAGTGTT AAAAAAACCRCRCRCAAACCTAA 54
RUNX3 YGTYGTTTTTTGYGTTTTGAGGTT ACTTAAATCTACRAAAATACRCATAACAA 55
TFAP2C GGGGAGGAGTTATGATAATTTTT AACCTTACTATCCRAATCACTAA 55
TFPI2 GTATTYGGGTYGTTTGGAGT TCCTAAACAACATCRCCCAATA 57
TIAM1 GTTTTGATAGTTTYGATTGGTAGATT ACRAAACAACCRTACCCCTAA 59
TMEFF2 TTGTTTTTTYGTYGGGTGTTATTGTTAT AACAAACRACTTCCRAAAAACACAAA 55
VGLL3 GAAGGTGTTYGYGTATGGGT CCRCAACTACCRCCTCTAT 57
qPCR
CDH13 AATCCACAAACAAGCTGTTCC GTTTCCCTGAATCTGTCACCA 57
CLDN6 CTTCGCAGTGCAGCTCCTT ACAGGAGACCAGGCCATTC 57
C16orf62 AGCTGTGTGAGACGGTGATG GTTGAGCTTGTTGTTGCGTAG 57
FBN2 TGGATTTTGTTCCCGTCCTA CCACCATTCATGCATCTCAC 55
FNBP1 TGCAAAGCAACTCAGGAATCT TTCATTTCGTTCAGGTTGGAA 57
ID4 CCGAGCCAGGAGCACTAGAG CTTGGAATGACGAATGAAAACG 60
RBP1 AGGCATAGATGACCGCAAG CTCATCACCCTCGATCCAC 62
RBP4 CTTTCTGCAGGACAACATCG TCCTCGGTGTCTGTGAAGGT 59
TFPI2 GTCGATTCTGCTGCTTTTCC CAGCTCTGCGTGTACCTGTC 60
TMEFF2 CAATGGGGAGAGCTACCAGA TGGACTCCATCTCCAGATCC 62
HMBS ACATGCCCTGGAGAAGAATG TTGGGTGAAAGACAACAGCA 57
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Extraction and bisulphite modification of genomic DNA. The
methods used for the preparation of genomic DNA and its
bisulphite modification have been reported previously (13-15).
Briefly, TRIzol (Invitrogen Inc., Calsbad, CA, USA) was used
to extract genomic DNA from the cell lines or proteinase K
digested tissues (16). Then 2 μg of genomic DNA was
denatured by treatment with NaOH at 37˚C for 15 min. This
was then modified using a mixture of 5 M sodium bisulphite
(Sigma-Aldrich) and 0.72 μM hydroquinone (Sigma-Aldrich)
for 4 h at 56˚C. The samples were purified using UltraClean
PCR Clean-up kit (MO BIO Laboratories, Inc., Carlsbad,
CA, USA), desulfonated with NaOH for 15 min at 37˚C,
precipitated with ethanol and sodium acetate, and finally
resuspended in 100 μl of Ultra Pure Water (Fisher Biotec
Australia, Wembley, WA, Australia).
Measurement of DNA methylation. DNA methylation
analysis was performed as described previously (15). Briefly,
bisulphite modified DNA was amplified with primers and
PCR conditions which did not discriminate between methy-
lated and unmethylated sequences and did not amplify
unmodified DNA. The primers and annealing temperatures
are summarized in Table I. The PCR was carried out using a
Rotor-Gene 3000 (RG3000, Corbett Life Science, Mortlake,
NSW, Australia) in a 15 μl reaction volume containing 5 μl
of water, 0.75 μl of each 10 μM primers, 7.5 μl of 2X
QuantiTect SYBR-Green PCR Master Mix (Qiagen Gmbh,
Hilden, Germany) and 1 μl of bisulphite modified DNA.
Reactions were started by initial denaturation at 95˚C for
15 min, followed by 45 cycles each of 20 sec at 95˚C then
45 sec for annealing and extension. The PCR was finished
with a final extension at 72˚C for 4 min. Melt curve analysis
was performed immediately after amplification by measuring
the reduction in the fluorescence of the SYBR-Green I during
a linear temperature transition from 60˚C to 95˚C at a rate
of 0.5˚C/sec. The -dF/dT curves were generated from the
fluorescence data using RG3000 application software version
6.0. Bisulphite modified DNA from lymphocytes of healthy
donors was used for the unmethylated control, and CpG
methylase (M.Sss1, New England Biolabs Inc., Ipswich, MA,
USA) treated lymphocyte DNA for the methylated control.
The extent of methylation was assessed from the -dF/dT
curves using our standard protocol. Briefly, a curve which
was almost identical to the methylated control was scored
as 3+, a curve whose melting temperature was closer to
methylated control than the unmethylated control was scored
as 2+, a curve which was almost identical to unmethylated
control was scored 0, and the rest were scored as 1+. All
assessment was undertaken independently by two investi-
gators (S.T. and E.S.) and, if their opinions differed,
consensus was reached by discussion.
Measurement of gene expression by quantitative reverse
transcription-PCR. Total RNA was extracted from cell
lines by TRIzol, and treated with the TURBO DNA-free
Kit (Ambion). The concentration of the RNA was measured
spectrophotometrically using the ND-1000 (NanoDrop
Technologies, Wilmington, DE, USA). The cDNA was
synthesized from the RNA using the SuperScript II First-
Strand Synthesis System for RT-PCR (Invitrogen Inc.)
according to the manufacturer's instruction. Quantitative
real-time reverse transcription-PCR (qPCR) was performed
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Table II. The methylation status of studied 19 genes in esophageal squamous carcinoma cell lines.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
KYSE-170 KYSE-510 KYSE-1170 SUm/c OE21
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BNIP3 U U U U U
CDH13 M M M M M
CLDN6 M M M M M
C16orf62 M M M M U
DCBLD2 U U U U U
FBN2 M M U U U
FNBP1 M U M U U
ID4 U U U M U
MLF1 U U U U U
NRG1 U U U U U
PRDM2 U U U U U
RBP1 M M M U M
RBP4 M M M U U
RUNX3 U U U U U
TFAP2C U U U U U
TFPI2 M M M U U
TIAM1 U U U U U
TMEFF2 M M M M M
VGLL3 U U U U U
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Figure 1. Methylation and expression of CLDN6, FBN2, RBP1, RBP4, TFPI2 and TMEFF2 in esophageal squamous cell carcinoma cell lines. (a)
Methylation in the esophageal squamous cell carcinoma cell line KYSE-170 cultured with either aza-dC or vehicle. Bisulphite modified DNA was amplified
using primers and PCR conditions (Table I). These were specific for bisulphite modified DNA, did not discriminate between methylated and unmethylated
sequences, and did not amplify unmodified DNA. The PCR products were melted by increasing the temperature from 60 to 95˚C, rising 0.5˚C at each step,
waiting 30 sec on the first step then 5 sec for each step thereafter. Data were collected and analyzed using the Melt Curve Analysis function of the RG3000
application software. The melt curves for unmethylated (light dotted line) and methylated (light solid line) controls and cell lines treated with vehicle (dark
solid line) or aza-dC (dark dotted line) are shown. The horizontal axis represents temperature and the vertical axis -dF/dT. (b) Gene expression in 5
esophageal squamous cell carcinoma cell lines treated either with aza-dC (shaded bar) or with vehicle (white bar). The normalized relative expression of
the gene of interest was determined by dividing by the expression of the housekeeping gene HMBS. A white bar shows vehicle treatment and a shaded bar
shows aza-dC treatment. An M indicates a cell line in which methylation was measured.
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on the RG3000 using the QuantiTect SYBR-Green PCR Kit
(Qiagen). The PCR reaction was carried out in a 10 μl reaction
mixture consisting of 3 μl of water, 5 μl of 2X QuantiTect
SYBR-Green PCR Master Mix, 0.5 μl of each 10 μM primers
and 1 μl of the first-strand cDNA. The primers and annealing
temperatures are listed in Table I. For each sample the amount
of the target and housekeeping gene hydroxymethylbilane
synthase (HMBS) was determined using a calibration curve.
The expression of the gene of interest was normalized to
HMBS.
Statistical analysis. Statistical analysis was performed using
GraphPad Prism version 4.02 for Windows (GraphPad Soft-
ware, San Diego, CA, USA). The grade of methylation was
compared between tissues using the ¯2 test. Differences
were considered significant when P<0.05.
Results
Identification of methylated genes. We determined, in a panel
of 5 different esophageal squamous cell carcinoma cell lines,
the methylation status of 19 genes which we had previously
shown to be significantly methylated in esophageal adeno-
carcinoma tissues and cell lines. Methylation was detected
in one or more of the esophageal squamous cell carcinoma
cell lines for CDH13, CLDN6, C16orf62, FBN2, FNBP1,
ID4, RBP1, RBP4, TFPI2 and TMEFF2, but not for BNIP3,
DCBLD2, MLF1, NRG1, PRDM2, RUNX3, TFAP2C,
TIAM1, or VGLL3 (Table II).
To determine if methylation was associated with silencing
of gene expression, mRNA expression was measured by
qPCR in each of the aza-dC and vehicle treated esophageal
squamous cell carcinoma cell lines. Treatment with aza-dC
resulted in a reduction in methylation (Fig. 1a) and an increase
in expression for CLDN6, FBN2, RBP1, RBP4, TFPI2
and TMEFF2 (Fig. 1b), suggesting an association between
methylation and suppression of expression of these genes in
the cell lines examined. However, there was not a correlation
between methylation and altered expression for CDH13,
C16orf62, FNBP1 and ID4 (data not shown).
Methylation in esophageal squamous cell carcinoma.
Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2 and
TMEFF2 was measured in tumor tissue and mucosa of
matched proximal resection margins from patients who
had had an esophagectomy for esophageal squamous cell
carcinoma (Fig. 2). Each of the 6 genes was methylated more
frequently in the tumors than the resection margins. No
methylation of RBP1 or TMEFF2 was detected in any
resection margin. The methylation grade was significantly
greater in the tumor than in the epithelium of the resection
margin for CLDN6, FBN2, RBP4 and TFPI2 (P=0.0007,
P=0.0048, P=0.0002 and P<0.0001, respectively).
Discussion
Esophageal cancer is one of the most common malignancies
in the world, and with an overall 5-year survival of around
10% (2), one of the most lethal. Cancer develops in the
setting of increased or decreased expression of critical
genes. In addition to genetic alterations such as loss of
heterozygosity and point mutation, DNA methylation at
CpG islands is a common mechanism of gene inactivation
in human carcinogenesis (17,18). There are many reports
of methylation changes in esophageal adenocarcinoma and
its precursor lesions, with evidence for their role in tumor
progression (19-21). Less is known about the mechanism of
carcinogenesis and progression in esophageal squamous
cell carcinoma, especially with regards to changes in methy-
lation. Hence, identifying genes which are methylated in
esophageal squamous cell carcinoma may increase our
understanding of the underlying mechanisms in this cancer,
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Figure 2. (a) The frequency and extent of methylation in esophageal squamous cell carcinoma resection specimens. Methylation of each gene was measured in
cancer tissue (T) and matched epithelium from the proximal margin of specimens (N) resected for esophageal squamous cell carcinoma. The extent of
methylation was graded from 3+ (black) to 0 (white) as described in the Materials and methods. The methylation in the tumor tissue was compared to that in
the margin tissue by ¯2 analysis. (b) Typical examples of melting curves from specimens with different extents of methylation are shown, with the bold line
representing 3+ methylation to the dotted line representing 0.
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and potentially lead to prognostic biomarkers or new
therapeutic options.
In a previous study we had used expression profiling of
an esophageal adenocarcinoma cell line before and after
treatment with aza-dC to identify genes whose expressions
were increased by this treatment, and so were potentially
methylated. From this we identified 19 genes which were
frequently methylated in esophageal adenocarcinoma,
and not in normal esophageal epithelium (9,10). The purpose
of this current study was to determine if these genes
were methylated in esophageal squamous cell carcinoma
cell lines, and if so the frequency of their methylation in
tissues.
Of the 19 genes which were methylated in esophageal
adenocarcinoma, only 10 were methylated in at least 1 of
the 5 esophageal squamous cell carcinoma cell lines
which we examined. We demonstrated that demethylation
of 6 of these methylated genes (CLDN6, FBN2, RBP1, RBP4,
TFPI2 and TMEFF2) was associated with an increase in
mRNA expression in the esophageal squamous cell carcinoma
cell lines. This suggests that the methylation we measured
was associated with gene silencing. Four genes (CDH13,
C16orf62, FNBP1 and ID4) did not consistently show an
inverse relationship between methylation and mRNA
expression. This is in contrast to our finding that methy-
lation of these same genes was associated with a reduction
in mRNA expression in the esophageal adenocarcinoma
cell lines (unpublished data). There are several possible
explanations for the difference between the results from
cell lines from the two different types of esophageal
cancer. It is possible that we measured methylation in a
region which is not responsible for repression of mRNA
transcription. If this were so, it would mean that in the
esophageal adenocarcinoma cell lines a region critical
for repression was also concordantly methylated, but not
in the esophageal squamous cell carcinoma cell lines.
Another possibility is that the up-regulation of mRNA
expression in the esophageal adenocarcinoma cell lines
was secondary to the demethylation of other silenced
genes, genes which are not methylated in the esophageal
squamous cell carcinoma cell lines. Interestingly, the
frequency of methylation of these three genes in the eso-
phageal squamous cell carcinoma clinical specimen was
higher than that in the matched normal epithelium, even
though the increase was not statistically significant (data
not shown).
Products of the claudin family of genes play an integral
role in the formation and function of tight junctions (22),
and their over- or under-expression has been reported in a
number of cancers (22). The majority of studies have focused
on CLDN1, CLDN3, CLDN4, CLDN7 and CLDN10. Little
is known about the role of CLDN6 in cancer, but changes
in the distribution pattern of claudins including CLDN6 in
suprabasal epidermal cells were observed in a mouse model
of skin tumorigenesis (23). Our findings of the methylation
of CLDN6 suggest the possibility of its involvement in eso-
phageal tumorigenesis.
This is the first report of the methylation of CLDN6,
FBN2, RBP4, TFPI2 and TMEFF2 in esophageal squamous
cell carcinoma. Interestingly, only these 5 genes were
methylated in both major types of esophageal cancer, the
other 13 genes in our study were methylated in adeno-
carcinoma but not squamous cell carcinoma. Future studies
are required to correlate the silencing of these genes with
clinicopathological parameters, including outcome, and to
determine the relevance of this difference in methylation to
the difference in biology of squamous cell carcinoma and
adenocarcinoma.
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